share_log

EF Hutton Reiterates Buy on Coeptis Therapeutics, Maintains $6 Price Target

Benzinga ·  Mar 29, 2023 10:38

EF Hutton analyst Michael King reiterates Coeptis Therapeutics (NASDAQ:COEP) with a Buy and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment